Reported 4 days ago
Sangamo Therapeutics Inc. experienced a significant decline in its stock, plunging over 50% during pre-market trading after Pfizer Inc. announced the termination of their partnership on a gene therapy program aimed at treating hemophilia A. Sangamo is currently exploring various options to continue the development of the treatment.
Source: YAHOO